A research institute maintains an ongoing registry of 30,000 patients who initiated therapy with a novel immunomodulatory agent for severe rheumatoid arthritis. Patients undergo protocolized clinical evaluations and provide serum samples every 6 months. Over a 10-year period, 42 patients in the registry develop a rare, atypical demyelinating syndrome. To evaluate whether pre-existing antibodies against a specific ubiquitous virus are associated with this adverse event, researchers select the 42 affected individuals. For each affected patient, they randomly identify four patients from the registry who had not developed the syndrome at the exact time the affected patient's diagnosis was made. The researchers then thaw and analyze the archived serum samples collected just prior to that time point for all 210 subjects to assess their viral antibody titers.
Which of the following best characterizes this research methodology and its primary epidemiological advantage?
- Nested case-control design; it minimizes control selection bias because the comparison group is drawn from the identical well-characterized source population that gave rise to the casesCevap
- BRetrospective cohort analysis; it allows researchers to directly calculate the true incidence rate of the demyelinating syndrome among patients with and without the viral antibodies
- CStandard case-control approach; it is the most statistically efficient method for analyzing rare outcomes while simultaneously controlling for recall bias regarding past exposures
- DProspective cohort methodology; it ensures that the temporal sequence between the viral antibody presence and the development of the demyelinating syndrome is definitively established
- ECase-cohort design; it selects a comparison group at the initiation of the registry, allowing the same control group to be utilized for investigating multiple different adverse events